These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 12942732)

  • 21. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer.
    Rouprêt M; Fromont G; Bitker MO; Gattegno B; Vallancien G; Cussenot O
    Urology; 2006 May; 67(5):1028-32. PubMed ID: 16698363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Editorial comment on: Prostate-specific antigen improves the ability of clinical stage and biopsy gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
    Stenman UH
    Eur Urol; 2007 Oct; 52(4):1074-5. PubMed ID: 17383813
    [No Abstract]   [Full Text] [Related]  

  • 23. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
    Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is radiotherapy useful in node-positive prostate cancer patients after radical prostatectomy?
    Van Poppel H
    Eur Urol; 2009 May; 55(5):1012-3. PubMed ID: 19261377
    [No Abstract]   [Full Text] [Related]  

  • 25. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
    Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
    BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
    Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second-line therapy after radical prostatectomy failure: for whom? When? How?
    Aus G
    Eur Urol; 2007 May; 51(5):1155-7; discussion 1157-8. PubMed ID: 17307285
    [No Abstract]   [Full Text] [Related]  

  • 29. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
    Carver BS; Bianco FJ; Scardino PT; Eastham JA
    J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The case against extended lymph-node dissection for prostate cancer.
    Huland H
    Nat Clin Pract Urol; 2006 Sep; 3(9):456-7. PubMed ID: 16964181
    [No Abstract]   [Full Text] [Related]  

  • 33. [Long-term outcome of radical prostatectomy in an observation period of at least 10 years].
    Fischer C; Schreiber A; Altwein JE
    Aktuelle Urol; 2005 Apr; 36(2):131-5. PubMed ID: 15902573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
    Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL
    J Natl Cancer Inst; 2006 Oct; 98(19):1420-4. PubMed ID: 17018789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of minute adenocarcinomas of prostate at radical prostatectomy.
    Truskinovsky AM; Sanderson H; Epstein JI
    Urology; 2004 Oct; 64(4):733-7. PubMed ID: 15491711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of biochemical failure on long-term clinical outcome after radical prostatectomy for prostate cancer in Japan.
    Egawa S; Matsui Y; Matsumoto K; Suyama K; Arai Y; Kuwao S; Baba S
    Prostate Cancer Prostatic Dis; 2004; 7(2):152-7. PubMed ID: 15175664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate-specific antigen adjusted for total prostatic tumor volume as a predictor for outcome after radical prostatectomy.
    Hayashi N; Urashima M; Ikemoto I; Kuruma H; Arai Y; Kuwao S; Baba S; Egawa S
    Prostate Cancer Prostatic Dis; 2007; 10(1):60-5. PubMed ID: 17003775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Substaging pathologically organ confined (pT2) prostate cancer: an exercise in futility?
    van der Kwast TH
    Eur Urol; 2006 Feb; 49(2):209-11. PubMed ID: 16417961
    [No Abstract]   [Full Text] [Related]  

  • 39. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy.
    Shariat SF; Kattan MW; Song W; Bernard D; Gottenger E; Wheeler TM; Slawin KM
    Cancer Res; 2003 Sep; 63(18):5874-8. PubMed ID: 14522912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.